|
|
|
|
| LEADER |
00000cam a2200000I 44500 |
| 001 |
b9171302 |
| 003 |
CoU |
| 005 |
20170721045012.6 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
170710s2017 enka ob 001 0 eng d |
| 020 |
|
|
|a 9780128124406
|q (electronic bk.)
|
| 020 |
|
|
|a 0128124407
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128124390
|
| 035 |
|
|
|a (OCoLC)scd993254670
|
| 035 |
|
|
|a (OCoLC)993254670
|
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OPELS
|d IDEBK
|d EBLCP
|
| 049 |
|
|
|a GWRE
|
| 050 |
|
4 |
|a RM171.5
|
| 100 |
1 |
|
|a Hedner, U.
|q (Ulla),
|e author.
|0 http://id.loc.gov/authorities/names/n99803729.
|
| 245 |
1 |
0 |
|a Treating life-threatening bleedings :
|b development of recombinant coagulation factor VIIa /
|c Ulla K.E. Hedner.
|
| 246 |
3 |
0 |
|a Development of recombinant coagulation factor VIIa.
|
| 264 |
|
1 |
|a London :
|b Academic Press,
|c [2017]
|
| 300 |
|
|
|a 1 online resource :
|b illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent.
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia.
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Front Cover; Treating Life-Threatening Bleedings; Copyright Page; Contents; About the Author; Preface and Acknowledgments; 1. Classical Bleeding Disease (Hemophilia); 1.1 The History of Hemophilia; 1.2 The Treatment of Hemophilia; 1.2.1 Fraction 1-0; 1.2.2 The clinical use of Fraction 1-0; 1.2.3 Prophylaxis in severe hemophilia; References; 2. My Encounter With Hemophilia (1959-82); 2.1 The Coagulation Laboratory in Malmö; 2.2 Hemophilia Patients With Inhibitors, and a Method to Stop Bleeding in These Patients; 2.3 Plasma FVIIa for Hemophilia Patients.
|
| 505 |
8 |
|
|a 2.4 Treatment for the First Patients With FVIIa2.5 Potential Development of FVIIa to Be Used in Hemophilia; References; 3. The First Years at Novo Nordisk; 3.1 Recruitment by Novo Nordisk, 1983; 3.2 Hematology at Novo Industri During the 1980s; 3.2.1 The history of heparin and Novo Industri; 3.2.2 The development of modified heparins; 3.2.3 The development of LMWH at Novo Industri; 3.2.4 Substances to dissolve clots (thrombi); 3.2.5 The introduction of FVII at Novo Industri; References; 4. The Development of Recombinant FVIIa (rFVIIa) (1985-88); 4.1 Background and Start.
|
| 505 |
8 |
|
|a 4.2 Work on Recombinant FVIIa4.2.1 The organization of the hemostasis group; 4.2.2 Production challenges; 4.2.3 The development of necessary assays; 4.2.4 Characterization of the rFVIIa molecule; 4.2.5 Effects and side effects: preclinical animal studies; 4.3 Treatment of the First Patient With rFVIIa, 1988; References; 5. The Further Use and Development of rFVIIa (1989-96); 5.1 The Prompt Use of rFVIIa; 5.2 rFVIIa as a "Compassionate Use" Product in the United States; 5.3 Plans for the Clinical Development of rFVIIa; 5.4 The Merger of Novo and Nordisk Gentofte 1989 and Its Consequences.
|
| 505 |
8 |
|
|a 5.5 The Development and Licensing of rFVIIa 1990-965.6 The Development of Production Capacity and the US License; 5.7 Blood Product Advisory Committee, 1996; 5.8 Some Final Reflections; References; 6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors; 6.1 "Orphan Drug Act"; 6.2 Patent Rights (Intellectual Property); References; 7. Treatment With rFVIIa in Malmö (1996-99); 7.1 Part-Time Employment at the Coagulation Clinic in Malmö (1996-90); 7.2 The Third "Key Patient"; 7.3 What Did This Patient Teach Us?; References; 8. The Launching and Uses of rFVIIa.
|
| 505 |
8 |
|
|a 8.1 The Launching of rFVIIa (1996-2000)8.2 rFVIIa for Use in Areas Other Than Hemophilia; 8.2.1 rFVIIa and platelet dysfunctions; 8.2.2 rFVIIa and liver diseases; 8.2.3 rFVIIa and patients with a normal coagulation system; 8.2.4 rFVIIa and trauma; 8.2.5 rFVIIa and patients with cerebral hemorrhages; References; 9. Mechanism of Action and Dosage; 9.1 Mechanism of Action; 9.2 Dosage; References; 10. The Continued Development of rFVIIa During the 2000s; 10.1 rFVIIa-Potential Long-term Effect; 10.1.1 The distribution in the blood of injected rFVIIa.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed July 11, 2017)
|
| 650 |
|
0 |
|a Blood coagulation factors.
|0 http://id.loc.gov/authorities/subjects/sh85014975.
|
| 650 |
|
0 |
|a Blood coagulation factor VIII.
|0 http://id.loc.gov/authorities/subjects/sh85014972.
|
| 650 |
|
0 |
|a Blood coagulation disorders
|x Treatment.
|
| 650 |
|
0 |
|a Hemophilia
|x Treatment.
|
| 856 |
4 |
0 |
|u https://colorado.idm.oclc.org/login?url=http://www.sciencedirect.com/science/book/9780128124390
|z Full Text (via ScienceDirect)
|
| 907 |
|
|
|a .b9171302x
|b 03-19-20
|c 08-07-17
|
| 998 |
|
|
|a web
|b 08-07-17
|c b
|d b
|e -
|f eng
|g enk
|h 0
|i 1
|
| 907 |
|
|
|a .b9171302x
|b 07-02-19
|c 08-07-17
|
| 944 |
|
|
|a MARS - RDA ENRICHED
|
| 907 |
|
|
|a .b9171302x
|b 08-07-17
|c 08-07-17
|
| 915 |
|
|
|a I
|
| 956 |
|
|
|a ScienceDirect ebooks
|
| 956 |
|
|
|b ScienceDirect All Books
|
| 999 |
f |
f |
|i 1c5a4a22-7fde-5638-8b92-91efc48d1e40
|s f420d435-48e1-5359-ace9-f915cc6ffea5
|
| 952 |
f |
f |
|p Can circulate
|a University of Colorado Boulder
|b Online
|c Online
|d Online
|e RM171.5
|h Library of Congress classification
|i web
|n 1
|
